The trajectory of Sildenafil presents a complex picture for investors. While the initial launch generated substantial returns, the expiration of its exclusive rights opened the door to generic versions, dramatically https://bookmarkspy.com/story23250757/the-copyright-and-big-pharma-a-risky-opportunity